NCT02940496 - Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2016

Primary Completion Date

August 9, 2023

Study Completion Date

August 9, 2023

Conditions

BCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaHepatitis C InfectionRefractory Liver CarcinomaStage III Hepatocellular Carcinoma AJCC v7Stage IIIA Hepatocellular Carcinoma AJCC v7Stage IIIB Hepatocellular Carcinoma AJCC v7Stage IIIC Hepatocellular Carcinoma AJCC v7Stage IV Hepatocellular Carcinoma AJCC v7Stage IVA Hepatocellular Carcinoma AJCC v7Stage IVB Hepatocellular Carcinoma AJCC v7

Interventions

DRUG

Elbasvir/Grazoprevir

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Ribavirin

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER